BRIEF published on 07/06/2026 at 22:10, 29 days 9 hours ago Abivax Completes its $920 Million Public Offering Biotechnology Actions Funding Abivax Public Offering
BRIEF published on 07/06/2026 at 22:10, 29 days 9 hours ago Abivax lève 920 millions de dollars lors d'une offre publique Biotechnologie Abivax Rectocolite Hémorragique Offre Publique Actions De Dépôt Américaines
BRIEF published on 07/06/2026 at 22:10, 29 days 9 hours ago Abivax Secures $920 Million in Public Offering Biotechnology Abivax Ulcerative Colitis Public Offering American Depositary Shares
PRESS RELEASE published on 07/06/2026 at 22:05, 29 days 9 hours ago Abivax annonce la réalisation de son offre au public de 920 millions de dollars Abivax réalise son offre publique de 920 millions de dollars pour le développement de thérapies biotechnologiques. Les actions sont cotées sur Euronext Paris et le Nasdaq Biotechnologie Abivax Offre Publique Thérapies Cotées
PRESS RELEASE published on 07/06/2026 at 22:05, 29 days 9 hours ago Abivax annonce la réalisation de son offre au public de 920 millions de dollars Abivax annonce la réalisation de son offre au public de 920 millions de dollars. La société de biotechnologie lève des fonds pour ses thérapies contre les maladies inflammatoires Biotechnologie Abivax Offre Publique Maladies Inflammatoires Millions De Dollars
PRESS RELEASE published on 07/06/2026 at 22:05, 29 days 9 hours ago Abivax Announces Closing of $920 Million Public Offering Abivax closes $920 million public offering, strengthening financial position. Proceeds to support operations until Q4 2029. Leerink Partners, Morgan Stanley, Piper Sandler, Guggenheim Securities involved in the offering Financial Position Abivax Morgan Stanley Public Offering Leerink Partners
BRIEF published on 07/02/2026 at 08:05, 1 month 2 days ago Abivax conclut une offre d'ADS avec succès Biotechnologie Abivax Investissements Ads Offre
BRIEF published on 07/02/2026 at 08:05, 1 month 2 days ago Abivax successfully concludes an ADS offer Biotechnology Abivax Offer Ads Investments
BRIEF published on 07/02/2026 at 08:05, 1 month 2 days ago L'offre d'Abivax rapporte 920 millions de dollars suite à l'exercice de surallocation. Biotechnologie Abivax Obefazimod Augmentation De Capital Offre ADS
BRIEF published on 07/02/2026 at 08:05, 1 month 2 days ago Abivax's Offering Yields $920M Following Over-Allotment Exercise Biotechnology Abivax Obefazimod Capital Increase ADS Offering
Published on 08/05/2026 at 02:10, 5 hours 47 minutes ago Kleen Hy-Dro-Gen Inc. Is Pleased to Announce Dual ISO 9001:2015 and TSSA Certifications, Bolstering Operational Quality and Technical Safety Governance
Published on 08/04/2026 at 22:30, 9 hours 27 minutes ago Nextech3D.ai Provides Update on Acquisition of Remaining ARway Shares
Published on 08/04/2026 at 17:00, 14 hours 57 minutes ago Moderna annonce le début d'un essai clinique de phase 1 portant sur l’ARNm-1469, son vaccin expérimental contre l'ébolavirus de Bundibugyo
Published on 08/04/2026 at 16:25, 15 hours 32 minutes ago ACCESS Newswire to Host Second Quarter Earnings Conference Call on August 11, 2026
Published on 08/05/2026 at 07:45, 12 minutes ago Schaeffler AG expands partial retirement offer in Germany
Published on 08/05/2026 at 07:35, 22 minutes ago Lenzing Reports Strongly Improved Half-Year Results and Accelerates Strategic Transformation Agenda
Published on 08/05/2026 at 07:30, 27 minutes ago Q2 2026: ElringKlinger maintains strong momentum in profitable growth and E-Mobility ramp-ups
Published on 08/05/2026 at 07:30, 27 minutes ago ZEAL continues its growth trajectory and reports highest first-half revenue in the company’s history
Published on 08/05/2026 at 07:30, 27 minutes ago voestalpine AG: voestalpine reports solid performance in the first quarter of 2026/27
Published on 08/04/2026 at 19:16, 12 hours 41 minutes ago Covivio - Rapport financier semestriel 2026
Published on 08/04/2026 at 18:32, 13 hours 25 minutes ago Capital et droits de vote au 31 juillet 2026
Published on 08/04/2026 at 18:32, 13 hours 25 minutes ago Total number of voting rights and shares making up the share capital at July 31, 2026
Published on 08/04/2026 at 17:45, 14 hours 12 minutes ago INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
